Abstract
Despite the advances of new modern multidisciplinary treatments of head and neck cancers, the rate of locoregional recurrences remains high. The multimodal systemic treatment with cetuximab together with platinum-based chemotherapy associated with 5-fluorouracil or, more recently, with taxanes brings benefits regarding survival, but remains a palliative treatment. Re-irradiation as the only treatment method or after salvage surgery, in cases where it is feasible, represents a potentially curative option, using techniques with intensity-modulated radiotherapy (IMRT) or even stereotactic body radiosurgery (SBRS). However, the rate of severe toxicity remains significant and the selection of patients must be carefully made. Combining immunotherapy with re-irradiation may provide new perspectives for cancer treatments of the head and neck, taking into account the immunogenic effect of radiation therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
